Skip to main content
Irving Loh, MD, Cardiology, Thousand Oaks, CA

IrvingKentLohMDFACC FAHA FCCP FACP

Cardiology Thousand Oaks, CA

Echocardiography, Non-Invasive Cardiology, Preventive Cardiology

Ventura Heart Institute; Co-Founder & Chief Medical Officer, INFERMEDICA; Past Chair, Technology & Innovation Committee, California Chapter, American College of Cardiology; Member, AI4H, Artificial Intelligence (AI) for Symptom Assessment & AI for Clinical Evaluation/World Health Organization; Senior Advisor - Cardiovascular Services, MORE Health Inc; Global Panel/MIT Technology Review

Dr. Loh is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Loh's full profile

Already have an account?

  • Office

    Ventura Heart Institute
    555 Marin Street, Suite 210
    Thousand Oaks, CA 91360
    Phone(866) 954-3466
    Fax(888) 419-3230
  • Is this information wrong?

Summary

  • Board certified internist & subspecialty certified cardiac specialist - emphasis on preventive cardiology. Original cardiology consultant for Doximity. He founded & directed the Ventura Heart Institute (education, research & preventive cardiovascular programs). Dr. Loh is a former Asst Prof Med UCLA School of Medicine & former Asst Clin Prof Med UC Irvine. Current Adjunct Lecturer, Stanford Univ School of Medicine. Member AI4H (AI for symptom assessment) (AI for Clinical Evaluation)/World Health Organization. UC Berkeley (PBK as junior), MD UC San Francisco (Regents Scholar; AOA as junior), Internal Medicine Residency UCSF. Lipid research National Heart, Lung & Blood Institute at National Institutes of Health (NIH) in both intramural (Molecular Diseases/Lipid Metabolism Branch) & extramural (Cardiac Diseases Branch; Division of Heart and Vascular Diseases) divisions. Faculty in both Departments of Cardiology & Cardiac Surgery at Cedars-Sinai. In private practice, chaired HCA Los Robles Hospital IRB, founded BioEthics Committee, directed echocardiography lab. Principal investigator on over 160 cardiovascular clinical trials (primarily phase 1, 2, 3 trials in dyslipidemia, e.g., PCSK9 mAb's, CETP inhibitors, heart failure, hypertension). In 1987, he wrote a bespoke electronic health record system. He has presented at RAND, USC School of Business, UCLA Anderson School of Business, Mayo Clinic in Rochester MN, & at both UC Berkeley's Center for Information Technology Research in the Interest of Society & the School of Public Health & at Harvard School of Public Health. He has presented at TEDx (http://youtu.be/b51KhIy3cA0) on how medical advances are validated. Chief Medical Advisor to Confideo Lab/DoctorVirtualis (virtual reality), Director CV Services for MORE Health, Lead Contributor - Sermo's Cardiology Hub, & Chair of Technology Committee of CA Chapter of ACC, Co-founder & CMO of Infermedica (artificial intelligence). Member - Global Panel/MIT Tech Review

Education & Training

  • Cedars-Sinai Medical Center
    Cedars-Sinai Medical CenterFellowship, Cardiovascular Disease, 1979
  • National Institutes of HealthPost-Doctoral Fellowship, Research, 1974 - 1977
  • UCSF
    UCSFResidency, Internal Medicine, 1974
  • UCSF
    UCSFClass of 1972

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1974 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Information Technology grant recipient The Future Forum - London, UK, 2003
  • Alpha Omega Alpha (elected as Junior) University of California, San Francisco School of Medicine, 1971
  • Phi Beta Kappa (elected as Junior) University of California, Berkeley, 1968
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • A Dose-Dependent Increase in Mortality with Vesnarinone Among Patients with Severe Heart Failure.  
    Vesnarinone Trial Investigators, New England Journal of Medicine
  • Hobbs RE. Results of the ATLAS Study – high or low doses of ACE inhibitors for heart failure?  
    ATLAS Trial Investigators, Cleve Clin J Med
  • Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure.  
    ATLAS Study Group, Circulation
  • Join now to see all

Abstracts/Posters

  • Moexipril Versus Captopril in Patients with Mild to Moderate Hypertension.
    Loh IK, Tenth Scientific Meeting of the American Society of Hypertension; New York Hilton/Towers, New York, NY

Lectures

  • What You Need to Know About Preventing Cancer? 
    Melissa Belle Ford, Director for Prevention and Early Detection, Univ of Texas, M.D. A...
  • Relearning Optimism. 
    Terry Paulson, Ph.D
  • Television Report: The Prevention of Heart Disease -a five part series. 
    the Ventura Heart Institute education and screening program; KEYT Evening News; Santa Barbara, CA
  • Join now to see all

Other

  • Innovations in pharmaceuticals 
    IK Loh, Street Journal
    http://online.wsj.com/article/
  • Radio Interview: Health Care Reform: Initiatives to reduce federal impediments to the delivery of health care. 
    Loh IK
    The White House, Washington
  • Risk Factors in Premature Coronary Disease (Interview by Deborah Norville) 
    Loh IK, Guest
    NBC Studios, New York

Authored Content

  • ACC 2021: Convergence of Cardiovascular and Diabetic Therapies ContinueMay 2021
  • Here's What ISCHEMIA Really MeansNovember 2019
  • Here's What ISCHEMIA Really MeansNovember 2019
  • We Don't Have to Just Accept Patients Taking Health SupplementsFebruary 2019
  • We Don't Have to Just Accept Patients Taking Health SupplementsFebruary 2019
  • Join now to see all

Press Mentions

  • Dr. Loh: How Clinical Researchers Handle Pauses in Vaccine Trials
    Dr. Loh: How Clinical Researchers Handle Pauses in Vaccine TrialsNovember 1st, 2020
  • The Future of Cardio Care: Assessment, Genetics and AI
    The Future of Cardio Care: Assessment, Genetics and AIJanuary 3rd, 2020
  • Telemedicine and the Future of Healthcare Delivery
    Telemedicine and the Future of Healthcare DeliveryApril 28th, 2019
  • Join now to see all

Committees

  • Chair, Technology & Innovation Committee, California Chapter of American College of Cardiology 2019 - Present
  • Member, Artificial Intelligence for Symptom Assessment; International Telecommunication Union; World Health Organization 2019 - Present
  • Member, Executive Steering Committee of the National Health Policy Council 1993 - 1995
  • Member, Amgen’s Institutional BioSafety Committee
  • Member, State of California Department of Health Services Cardiovascular Disease Prevention Coalition
  • Member, Manuscript Review Board and Ad Hoc Editor for the Journal of Clinical Outcomes Management
  • Member, Expert Panel on Outcomes Evaluation and Research for the American Heart Association
  • Member, Advisory Board Company/Cardiology Preeminence Roundtable based in Washington DC
  • Executive Steering Committee member, West Lipid Association Board of Directors
  • Charter Member, Lipidologists of Los Angeles

Research History

  • Principal InvestigatorCardiovascular trials for Westlake Medical Research2010 - Present
  • Director & Principal InvestigatorVentura Heart Institute1985 - Present
  • National Heart, Lung and Blood Institute at the National Institutes of Health (NIH)Intramural (Molecular Diseases/Lipid Metabolism Branch) and extramural (Cardiac Diseases Branch; Division of Heart and Vascular Diseases) divisions1974 - 1977

Professional Memberships